Antiparasitic therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21628620.
- Also identified by DOI 10.4065/mcp.2011.0203 and PMC identifier 3104918.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Parasitic diseases affect more than 2 billion people globally and cause substantial morbidity and mortality, particularly among the world's poorest people. This overview focuses on the treatment of the major protozoan and helminth infections in humans. Recent developments in antiparasitic therapy include the expansion of artemisinin-based therapies for malaria, new drugs for soil-transmitted helminths and intestinal protozoa, expansion of the indications for antiparasitic drug treatment in patients with Chagas disease, and the use of combination therapy for leishmaniasis and human African trypanosomiasis.
Medical subject headings
- Anthelmintics
- Antiprotozoal Agents
- Helminthiasis
- Protozoan Infections